HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Images in Immunotherapy and Precision Oncology: Angiosarcoma of the Spleen and Liver.

Abstract
Primary splenic or hepatic angiosarcomas are ultra-rare and aggressive malignancies associated with poor prognosis. The mainstay treatments are surgical resection and chemotherapy. We report a case of angiosarcoma in a 50-year-old woman who presented with bruising, fatigue, ecchymosis, and hepatosplenomegaly. She was treated with the multi-kinase inhibitor sunitinib for 4 weeks before developing a splenic hemorrhage and succumbing. Recent studies have demonstrated the clinical benefit of immunotherapies in angiosarcomas. Additionally, sequencing techniques have showcased the diverse molecular aberrations involved in angiosarcomas, which offer opportunities for precision-matched targeted therapies such as inhibitors of the VEGF/VEGFR axis and PI3K/Akt/mTor pathway.
AuthorsAnagha Deshpande, Javier Munoz, Katalin Kelemen, Vrushali Dabak, Amr Hanbali, Razelle Kurzrock
JournalJournal of immunotherapy and precision oncology (J Immunother Precis Oncol) Vol. 6 Issue 1 Pg. 56-58 (Feb 2023) ISSN: 2590-017X [Electronic] United States
PMID36751660 (Publication Type: Case Reports)
Copyright© 2023.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: